Skip to content

Royalty Pharma plc

RPRX

CIK 0001802768

← back to feed
Revenue (TTM)
$2.39B
+5.1% YoY Q1 Mar 2026
Net Income (TTM)
$852.43M
−10.2% YoY Q1 Mar 2026
EPS Diluted (TTM)
$1.96
−6.8% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
72.7%
Q1 Mar 2026
Net Margin
35.7%
Q1 Mar 2026
Free Cash Flow (TTM)
—
Q1 Mar 2026
Cash
$586.4M
Q1 Mar 2026
Total Debt
$8.96B
Q1 Mar 2026
Shares Outstanding
388.13M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings